Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac enema is a hypertonic phosphate-based laxative (typically containing sodium acid phosphate and disodium phosphate). It acts as an osmotic agent, drawing water into the lumen of the colon to induce peristalsis and evacuation.
## Primary Indications
* Relief of occasional constipation.
* Bowel preparation prior to rectal examinations or endoscopic procedures.
## Adult Dosing
* **Standard dose:** One ready-to-use enema unit (typically 118–130 mL delivered volume).
* **Frequency:** Maximum 1 dose per 24 hours.
## Pediatric Dosing
* **Children 12 years and older:** Same as adult dose (one unit).
* **Children 2 to 11 years:** 0.5 to 1 unit (approx. 59 mL) depending on local protocol and severity of constipation.
* **Under 2 years:** Contraindicated without direct specialist supervision due to high risk of electrolyte disturbances.
## Dose Adjustments
* **Renal Impairment:** Exercise extreme caution. Contraindicated in patients with severe renal impairment due to the risk of hyperphosphatemia and hypocalcemia.
* **Geriatric Patients:** Use with caution; monitor for dehydration/electrolyte imbalance.
## Contraindications
* Hypersensitivity to phosphates.
* Congestive heart failure.
* Clinically significant renal impairment.
* Conditions where bowel obstruction or perforation is suspected (e.g., megacolon, inflammatory bowel disease, anal fissures).
* Presence of nausea, vomiting, or abdominal pain.
## Adverse Effects
* **Common:** Abdominal cramping, flatulence, rectal irritation/burning.
* **Serious:** Severe electrolyte shifts (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, metabolic acidosis, and symptomatic cardiac arrhythmias.
## Key Drug Interactions
* **Diuretics:** Increased risk of dehydration and electrolyte imbalances.
* **Calcium Channel Blockers:** Potential for enhanced electrolyte-induced arrhythmias.
* **Nephrotoxic drugs:** Concomitant use increases risk of acute phosphate nephropathy.
* **Parathyroid agents:** May interfere with therapeutic goals.
## Monitoring
* **Acute use:** Monitor for signs of dehydration (thirst, decreased urine output).
* **Post-procedural/Multiple doses:** Electrolyte panel (Serum phosphate, calcium, sodium, potassium) and renal function (BUN/SCr), particularly in susceptible patients.
## Clinical Pearls
* **Administration:** Position patient in the left lateral decubitus position (Sims' position). Lubricate the tip and insert gently; do not force insertion to avoid mucosal injury.
* **Absorption:** While minimally absorbed when used rectally in healthy individuals, significant systemic absorption can occur in the presence of mucosal damage or if utilized too frequently.
* **Hydration:** Always encourage adequate fluid intake before and after administration to mitigate osmotic fluid shifts.
***
*Disclaimer: This information is for educational purposes only and does not constitute medical advice. Verify all dosing and contraindications against institutional protocols and the manufacturer’s most recent package insert before prescribing or administering.*
